{Reference Type}: Letter
{Title}: Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.
{Author}: Hill AM;Elbirt D;
{Journal}: AIDS
{Volume}: 38
{Issue}: 9
{Year}: 2024 Jul 15
{Factor}: 4.632
{DOI}: 10.1097/QAD.0000000000003911